MedTrace Logo

Fasedienol

Drug

Drug Profile

Fasedienol (PH94B) is a first-in-class investigational pherine nasal spray candidate for social anxiety disorder. It is designed for rapid-onset, low-microgram intranasal administration and has been evaluated in Phase 3 studies. The product remains an investigational therapy.

Drug Class
Investigational pherine nasal spray
Approval Status
Investigational; in Phase 3 development
Mechanism of Action
Proposed mechanism regulates olfactory-amygdala fear/anxiety circuits and sympathetic autonomic tone without systemic distribution
Brand Names
  • fasedienol
  • PH94B
Indications
  • \Social anxiety disorder (SAD)\

Related News

Class Action Lawsuits Filed Against Atara, Ultragenyx, Mereo, and Vistagen Over Alleged Misstatements

Class action lawsuits allege false statements about clinical trial results and regulatory prospects at Atara Biotherapeutics, Ultragenyx, Mereo BioPharma, and Vistagen Therapeutics. The complaints cite failed Phase 3 studies for setrusumab in Osteogenesis Imperfecta and fasedienol for social anxiety disorder, along with manufacturing issues affecting Atara's tabelecleucel application. Investors have deadlines ranging from April to May 2026 to seek lead plaintiff status.